Literature DB >> 20136835

Rational design of dualsteric GPCR ligands: quests and promise.

Klaus Mohr1, Christian Tränkle, Evi Kostenis, Elisabetta Barocelli, Marco De Amici, Ulrike Holzgrabe.   

Abstract

Dualsteric ligands represent a novel mode of targeting G protein-coupled receptors (GPCRs). These compounds attach simultaneously to both, the orthosteric transmitter binding site and an additional allosteric binding area of a receptor protein. This approach allows the exploitation of favourable characteristics of the orthosteric and the allosteric site by a single ligand molecule. The orthosteric interaction provides high affinity binding and activation of receptors. The allosteric interaction yields receptor subtype-selectivity and, in addition, may modulate both, efficacy and intracellular signalling pathway activation. Insight into the spatial arrangement of the orthosteric and the allosteric site is far advanced in the muscarinic acetylcholine receptor, and the design of dualsteric muscarinic agonists has now been accomplished. Using the muscarinic receptor as a paradigm, this review summarizes the way from suggestive evidence for an orthosteric/allosteric overlap binding to the rational design and experimental validation of dualsteric ligands. As allosteric interactions are increasingly described for GPCRs and as insight into the spatial geometry of ligand/GPCR-complexes is growing impressively, the rational design of dualsteric drugs is a promising new approach to achieve fine-tuned GPCR-modulation.

Mesh:

Substances:

Year:  2010        PMID: 20136835      PMCID: PMC2839259          DOI: 10.1111/j.1476-5381.2009.00601.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  79 in total

1.  Labeling of rat heart muscarinic receptors using the new M2 selective antagonist [3H]AF-DX 384.

Authors:  M Entzeroth; N Mayer
Journal:  Biochem Pharmacol       Date:  1990-10-01       Impact factor: 5.858

2.  Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes.

Authors:  N H Lee; E E el-Fakahany
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

3.  Binding properties of nine 4-diphenyl-acetoxy-N-methyl-piperidine (4-DAMP) analogues to M1, M2, M3 and putative M4 muscarinic receptor subtypes.

Authors:  M Waelbroeck; J Camus; M Tastenoy; J Christophe
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

4.  New functionally selective muscarinic agonists.

Authors:  G Lambrecht; U Moser; U Grimm; O Pfaff; U Hermanni; C Hildebrandt; M Waelbroeck; J Christophe; E Mutschler
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

5.  Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions.

Authors:  J Ellis; M Seidenberg; M R Brann
Journal:  Mol Pharmacol       Date:  1993-09       Impact factor: 4.436

6.  Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics.

Authors:  W W Engel; W G Eberlein; G Mihm; R Hammer; G Trummlitz
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

7.  Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals.

Authors:  L Sterin-Borda; G Gorelik; E S Borda
Journal:  Clin Immunol Immunopathol       Date:  1991-12

Review 8.  Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics.

Authors:  W G Eberlein; W Engel; G Mihm; K Rudolf; B Wetzel; M Entzeroth; N Mayer; H N Doods
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

Review 9.  Polymethylene tetraamines as muscarinic receptor probes.

Authors:  C Melchiorre; A Minarini; P Angeli; D Giardinà; U Gulini; W Quaglia
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

10.  Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.

Authors:  J Ellis; J Huyler; M R Brann
Journal:  Biochem Pharmacol       Date:  1991-10-24       Impact factor: 5.858

View more
  30 in total

1.  Molecular pharmacology of G protein-coupled receptors. Editorial.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2010-03       Impact factor: 8.739

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

3.  The different ways through which specificity works in orthosteric and allosteric drugs.

Authors:  Ruth Nussinov; Chung-Jung Tsai
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

5.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Muscarinic receptors as model targets and antitargets for structure-based ligand discovery.

Authors:  Andrew C Kruse; Dahlia R Weiss; Mario Rossi; Jianxin Hu; Kelly Hu; Katrin Eitel; Peter Gmeiner; Jürgen Wess; Brian K Kobilka; Brian K Shoichet
Journal:  Mol Pharmacol       Date:  2013-07-25       Impact factor: 4.436

Review 7.  Novel Allosteric Modulators of G Protein-coupled Receptors.

Authors:  Patrick R Gentry; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

8.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

9.  Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.

Authors:  R Schrage; W K Seemann; J Klöckner; C Dallanoce; K Racké; E Kostenis; M De Amici; U Holzgrabe; K Mohr
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.